Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

while Biogen has an anti-CD38 antibody called felzartamab in phase 3, raising the prospect of a series of new-mechanism therapies for the disorder. "My son was diagnosed with IgA nephropathy long ...

Panelists discuss how early diagnosis of immunoglobulin A (IgA) nephropathy enables timely interventions that can ...

Panelists discuss how disease-modifying therapies for immunoglobulin A (IgA) nephropathy, though initially more expensive than symptomatic treatments, offer substantial long-term cost benefits by ...

ROCKVILLE, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Today, on IgA Nephropathy Awareness Day, the American Kidney Fund (AKF) proudly announces the creation of new educational resources for "A Step Ahead ...

A wave of new therapies is transforming care for glomerular diseases, and nowhere is the momentum faster than in immunoglobulin A (IgA) nephropathy. At the National Kidney Foundation (NKF ...

FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and providers ...

The European Commission’s standard approval of FILSPARI is a meaningful step forward for people living with IgA nephropathy across Europe,” said Dr. Jula Inrig, Chief Medical Officer at Travere ...

The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for sibeprenlimab for the treatment of immunoglobulin A nephropathy (IgAN) in adults.

Sparsentan is expected to be funded in England by 27 June 2025, within 90 days of the final guidance publication. IgA ...